Login to Your Account

AACR Roundup

Tuesday, October 22, 2013
• MEI Pharma Inc., of San Diego, announced results from a Phase I single-agent study of its investigational mitochondrial inhibitor drug candidate, ME-344, in patients with refractory solid tumors.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription